Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

CytoDyn hopes for Breakthrough label for HIV therapy
February 2017
SHARING OPTIONS:

VANCOUVER, Wash.—CytoDyn Inc. has filed a request with the FDA for Breakthrough Therapy Designation for PRO 140 for HIV-1 infection in treatment-experienced patients with virologic failure. Results from four completed and ongoing clinical trials suggest PRO 140 can address unmet medical needs for HIV-1 patients with uncontrolled viral load despite conventional antiretroviral therapy.
 
Dr. Nader Pourhassan, CytoDyn’s president and CEO, said: “Investigators from several sites have requested continued access to PRO 140 to allow patients to continue deriving clinical benefit and maintain HIV-1 viral suppression after the end of treatment in the CD02 Phase 3 combination therapy study. Seven patients have entered the rollover study to receive continued access to PRO 140 after the completion of the 25-week treatment period in this study. Additionally, 10 patients in the ongoing Phase 2b extension arm of Monotherapy trial have shown suppressed viral load for two years.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.